Alberto Mello e Silva

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force

Maurizio Averna, Maciej Banach, Éric Bruckert et al. · Atherosclerosis · 2021 · 136 citations · Full text

Pharmacy, Cardiology, Pharmacotherapy +16

Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia

Roberto Ferrari, Carlos Aguíar, Eduardo Alegría et al. · European Heart Journal Supplements · 2016 · 101 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Evaluation of lipoprotein(a) in the prevention and management of atherosclerotic cardiovascular disease: A survey among the Lipid Clinics Network

Alberico L. Catapano, Lâle Tokgözoğlu, Maciej Banach et al. · Atherosclerosis · 2023 · 30 citations · Full text

Medicine, Cardiology, Preventive Medicine +13

The burden of atherosclerosis in Portugal

João Costa, Joana Alarcão, Francisco Araújo et al. · European Heart Journal - Quality of Care and Clinical Outcomes · 2020 · 22 citations · Full text

Medicine, Cardiology, Clinical Cardiology +16

Atherosclerosis: The cost of illness in Portugal

João Costa, Joana Alarcão, Alexandre Amaral‐Silva et al. · Revista Portuguesa de Cardiologia (English Edition) · 2021 · 14 citations · Full text

Pharmacy, Health Sciences, Cost-effectiveness Analysis +16